TEL AVIV, Israel, August 30, 2018 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ:
BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company
focused on oncology and immunology, today announced that its Chief
Executive Officer, Philip Serlin,
will present a company update at the 20th Annual Rodman &
Renshaw Global Investment Conference, sponsored by H.C. Wainwright
& Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis Hotel in
New York City.
The BioLineRx presentation is scheduled to start at 9:35 a.m.
EDT on Wednesday, September 5, 2018.
A live audio webcast of the presentation will be available online
on the Investor Page of the Company's website. An archive of the
event will also be available for those unable to listen live.
If you are an institutional investor, and would like to attend
the Company's presentation, please click on the following link
(http://www.rodmanevents.com) to register for the conference.
Once your registration is confirmed, you will be prompted to
log into the conference website to request a one-on-one meeting
with the Company.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology and immunology. The Company in-licenses novel
compounds, develops them through pre-clinical and/or clinical
stages, and then partners with pharmaceutical companies for
advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
multi-therapy platform, which has successfully completed a Phase 2a
study for relapsed/refractory AML, is in the midst of a Phase
2b study as an AML consolidation
treatment and has initiated a Phase 3 study in stem cell
mobilization for autologous transplantation; and AGI-134, an
immunotherapy treatment in development for multiple solid tumors,
which has recently initiated a Phase 1/2a study. In addition,
BioLineRx has a strategic collaboration with Novartis for the
co-development of selected Israeli-sourced novel drug candidates; a
collaboration agreement with MSD (known as Merck in the US and
Canada), on the basis of which the
Company is conducting a Phase 2a study in pancreatic cancer using
the combination of BL-8040 and Merck's KEYTRUDA®; and a
collaboration agreement with Genentech, a member of the Roche
Group, to investigate the combination of BL-8040 and Genentech's
atezolizumab in several Phase 1b/2
studies for multiple solid tumor indications and AML.
For additional information on BioLineRx, please visit the
Company's website at http://www.biolinerx.com, where you can review
the Company's SEC filings, press releases, announcements and
events. BioLineRx industry updates are also regularly updated on
Facebook, Twitter, and LinkedIn.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-646-863-6274
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com
SOURCE BioLineRx Ltd.